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Rheumatoid  factors (RF) 1 have been shown to have considerable heterogeneity of 
specificities for antigenic determinants on the IgG molecule (1, 2). Among monoclonal 
RF,  heterogeneity  has  been  also  demonstrated  by  the  presence  of different  cross- 
idiotype antigens that are thought to relate to differences in antibody-combining sites 
(3). In recent years, reports of RF that cross-react with non-IgG antigens has suggested 
that  still greater heterogeneity exists among  RF  than  previously thought  (4,  5).  In 
preliminary  publications  (6,  7)  we  have  reported  that  a  monoclonal  RF  (mRF) 
isolated from  the serum  of a  patient  with  Waldenstr6m's macroglobulinemia cross- 
reacted with DNA-nucleoprotein and that similar cross-reactive polyclonal RF appear 
to occur in pathologic fluids in a  variety of human  diseases. We now provide direct 
evidence that  certain  RF react with  an  antigen  that  appears  to  be present  on  both 
IgG  and  DNA-nucleoprotein.  In  addition,  evidence  is  presented  to  support  the 
hypothesis that  these RF comprised a  subset  which  is determined not only by their 
cross-reactivity with  DNA-nucleoprotein  but  by  the  presence  of  a  cross-idiotype 
antigen distinct from those previously identified among mRF  (3). 
Materials  and  Methods 
Preparation of Reagents.  An IgM x-RF (Bla mRF) was isolated by IgG-Sepharose (Pharmacia 
Fine Chemicals, Div. of Pharmacia, Inc., Piscataway, N. J.) affinity chromatography (8). The 
preparation was 98.7% IgM, 0.4% IgG, and 0.9% IgA. Clq was not detectable. Polyclonal RF 
(Orl)  was  isolated  in  a  similar  fashion.  Other  mRF  were  isolated  from  cryoglobulins as 
previously described (9). F(ab')2 and Fab fragments of Bla mRF were prepared by 2.0% pepsin 
(wt:wt) digestion at 37°C for 4 h at pH 4.0, and were isolated by G150-Sephadex (Pharmacia 
Fine Chemicals, Div. of Pharmacia, Inc.) chromatography. The Fab fragment was also prepared 
by trypsin digestion at  63°C.  (10)  Nuclei  and  DNA-nucleoprotein were  isolated from  calf 
thymus  (11).  Soluble  DNA-nucleoprotein  (sNP)  was  prepared  by  ultrasonic  disintegration 
(Sonifier, Heat Systems-Ultrasonics, Inc., Plainview, N.  Y.).  Concentrations of DNA-nucleo- 
protein were  determined  by  the  diphenylamine assay  for  DNA  and  micro-biuret assay for 
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1 Abbreviations used in this paper." ANF, antinuclear fluorescence; Bla mRF, an IgM rheumatoid factor; 
BSA, bovine serum albumin;  K0, association constant(s);  LE, lupus erythematosus;  McD, a monoclonal 
rheumatoid  factor without  DNA nucleoprotein reactivity; L. serum, serum from a patient with systemic 
lupus erythematosus known to have an anti-nucleoprotein  antibody without reactivity to aggregated IgG; 
MCTD,  mixed  connective-tissue disease; mRF,  monoclonal  rheumatoid  factor(s);  Orl,  a  polyclonal 
rheumatoid  factor; PBS, phosphate-buffered saline; RA, rheumatoid  arthritis;  RF, rheumatoid factor(s); 
RO, rheumatoid overlap; SLE, systemic lupus erythematosus; sNP, soluble-DNA nucleoprotein. 
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protein. Mono-, oligo-, and polynucleosomes were prepared from isolated calf thymus nuclei as 
described (12). The size of the mononucleosomes was confirmed as 11S by analytical uhracen- 
trifugation in a  Beckman model E ultracentrifuge (Beckman Instruments, Inc., Spinco, Div, 
Palo Alto, Calif.) Purified aggregated human  IgG was prepared as previously described (8). 
Solid-phase preparations of RNAase, DNAase, and pronase were prepared by conjugation to 
Sepharose using the method of Bing (13). 
Preparation of Antisera.  Antisera with cross-idiotypic  specificity for two groups ofmonoclonal 
anti-y-globulins: the Wa group, anti-Ma (an tuRF without DNA-nucleoprotein reactivity [anti- 
McD  in  this  study]);  and  the  Po  group,  anti-Lay  (an  mRF  without  DNA-nucleoprotein 
reactivity) were raised and characterized in a  previous study (3).  Antisera to Bla tuRF, Lay 
tuRF, and Orl RF were raised by a  minimum of 8 weekly immunizations of rabbits or goats 
with 0.5 mg of the respective protein in complete Freund's adjuvant. Antisera were absorbed 
with 0.2 ml of normal serum, 2.0 mg of Cohn Fraction II, and 2.0 mg each of a I¢- and }~-IgM 
protein without anti-T-globulin activity per ml of antiserum. F(ab')2 fragments of IgG isolates 
were prepared by pepsin digestion at 37°C for 18 h at pH 4.0, and isolated on Gl50-Sephadex. 
F(ab')2 preparations were further absorbed by passage over solid-phase I¢- and }~-IgM proteins 
without anti-T-globulin activity. 
Immunofluorescent Techniques.  Fluorescein-conjugated reagents and direct and indirect tech- 
niques for demonstrating antinuclear antibody were performed as previously described (14). To 
screen for the presence of cross-reactive RF in sera, tests employing blocking of the antinuclear 
fluorescence reaction (ANF) were performed. Equal volumes of a  dilution of the test serum 
which gave 2  + fluorescence, and  1 mg/ml solutions of aggregated IgG or sNP were incubated 
for 1 h at 20°C, centrifuged, and the ANF activity of the supemate compared to that of controls 
blocked with bovine serum albumin (BSA). Complete blocking by both aggregated IgG and 
sNP was considered a positive test for cross-reactive RF. Characterization of Bla and Orl ANF 
reactions on acid-eluted and histone-reconstitution tissues was performed as previously described 
(15,  16). 
Assays.  Reagents were labeled with I ~  using the lactoperoxidase-catalysed reaction previ- 
ously described (8). The sp act obtained were: tuRF: 0.1-0.25 #Ci/pg, Bla mRF F(ab')2:0.03 
#Ci//tg, sNP: 0.05/tCi//tg, polynucleosomes: 0.02 #Ci/#g, and human IgG: 0.03, #Ci/#g. The 
one-step competitive inhibition assay of l~I-Bla mRF  binding  to  IgG-Sepharose has  been 
described in  detail  (8).  Studies with  other radiolabeled mRF were  performed  in  the same 
manner. Briefly, 100 #1 buffer or inhibitor and  100 #1 I~I-mRF (~0.2 #g) were added to 250 
#1 of 1.25% suspension of IgG-Sepharose. 550/tl of phosphate-buffered saline (PBS) was added 
and the tubes rotated overnight at 4°C. Tubes were spun, washed three times with PBS, the 
pellet counted in a gamma counter (Beckman Instruments, Fullerton, Calif.), and the percent 
inhibition calculated. 
DNA-nucleoprotein coupled to Sepharose produced a ligand which was unable to bind Bla 
mRF; therefore, a double antibody technique was used for measuring t25I-sNP or ~25I-polynu- 
cleosomes binding.  I00/tl mRF or serum specimen was incubated at  20°C  for  10 min with 
either 100 #1 buffer or inhibitor. 100 #1 (l#g) t25I-sNP or 12nI-polynucleosomes and then 700 #1 
buffer were added. Tubes were rocked at 20°C for 1 h.  100 #1 of a goat anti-human Fc# was 
added. After 1 h at 20°C, the precipitate was collected, washed three times with PBS, counted, 
and the percent binding or the percent inhibition calculated. 
The  assay that  employed x25I-sNP was  used  for screening sera  for the  presence of cross- 
reactive RF. 2 #g of Bla mRF gave 50% binding which was completely inhibited by  10 #g 
aggregated IgG or 10 #g sNP. Equivalent binding by IgM anti-DNA nucleoprotein antibody 
isolated from serum from a patient with systemic lupus erythematosus (SLE) known to have an 
anti-nucleoprotein antibody without reactivity with aggregated IgG (L. serum) was inhibited 
by 10 #g sNP but not 10 #g aggregated IgG. The upper limit of binding for 55 normal sera was 
4.5% (mean +  2 SD). Sera with greater amounts of binding were further tested to determine if 
aggregated IgG  (10  #g)  blocked the binding. Greater than  50%  blocking was considered a 
positive test for cross-reactive RF. 
Hemagglutination  inhibition experiments  for  demonstrating cross-idiotypic specificity of 
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Results 
Characterization of Bla mRF Reactivity with Aggregated IgG and DNA-Nucleoprotein.  The 
cross-reactivity of Bla mRF with  a  nuclear antigen  was first demonstrated with  the 
ANF reaction (Fig.  1 A). The ANF reaction could be blocked with aggregated IgG at 
1 mg/ml (Fig.  1 B). In contrast the ANF reaction of the serum L. could not be blocked 
by aggregated IgG in concentration up to 20 mg/ml. 
The cross-reaction could also be demonstrated in gel diffusion as shown in Fig. 2 A. 
Confirmation that Bla mRF reacted with an antigen involving DNA and protein was 
obtained by the type of enzymatic digestion experiments illustrated  in Fig.  2 B. The 
possibility that the reactions were a result of contaminants, either DNA-nucleoprotein 
in the aggregated IgG or bovine IgG aggregates in DNA-nucleoprotein, was also ruled 
out  in  this experiment.  In addition,  it  is  known  that  Bla mRF does not  precipitate 
FIG.  I.  (A)  4-~m  mouse  liver  section  stained  with  0.06  mg/m[  [luorescein-labeled  Bla  mRF. 
Staining was obtained with concentrations as low as 0.002  mg/ml, x  1,350. (B) Fluorescence shown 
in (A) was blocked by incubating  1 mg/ml aggregated IgG with the fluorescein-labeled Bla mRF. 
Blocking was not obtained with  10 mg/ml BSA,  1 mg/ml DNA, or  1 mg/ml RNA. ×  1,350. AGNELLO, ARBETTER, IBANEZ DE KASEP, POWELL, TAN, AND JOSLIN  1517 
FIG. 2.  0.6%  agarose gel diffusion plates. Precipitation of Bla mRF I mg/ml with aggregated 10 
mg/ml lgG (agg IgG) and 3 mg/ml sNP (NP) (A). aggregated IgG treated with DNase (agg IgG 
DNased) or sNP treated with DNase (NP DNased), RNase (NP RNased), trypsin (NP TRY.), 
pronase (NP PRO.), or no enzyme (NP CON.) (B). 
with  bovine IgG  (8);  and  in  contrast  to  aggregated  IgG where  the  antigenicity  is 
increased by heating at 63°C,  the reactivity of similarly heated DNA-nucleoprotein 
with Bla mRF is decreased. The remote possibility that trace amounts of C lq in the 
Bla tuRF preparation were responsible for the reactions observed was eliminated by 
heating the mRF at 56 °  for 30 min before use. 
Cross-reactions of the type shown by Bla mRF could not be found among heterol- 
ogous  antisera  to  IgG,  sera  from  patients  with  SLE  that  gave  strong  precipitin 
reactions  with  DNA-nucleoprotein,  or  among eleven  other  IgM  g-mRF  that  gave 
strong precipitin reactions with aggregated IgG. 
A  sensitive competitive inhibition  radioimmunoassay had  been  previously devel- 
oped with  Bla  mRF  (8).  The  binding  of Bla  mRF  to  IgG-Sepharose in  this  assay 
could  be  maximally  inhibited  by  both  aggregated  IgG  and  DNA-nucleoprotein, 
whereas  control  proteins  and  nucleic  acids  gave  no  significant  inhibition.  Similar 
results could be demonstrated using a  F(ab')2 fragment of Bla mRF as shown in Fig. 
3.  The same effects of enzyme treatment shown in the precipitin experiments could 
also be demonstrated in the radioimmunoassay System. 
Further evidence that the cross-reaction was via the antigen-combining site of the 
mRF and not through nonspecific interaction of IgM with aggregated IgG and DNA- 
nucleoprotein  was  obtained  using  an  anti-idiotype  sera  to  Bla  mRF.  The  F(ab')z 
preparation  of this  antiserum  blocked the binding of Bla mRF to both  aggregated 
IgG and DNA-nucleoprotein over a range of dilution as shown in Fig. 4. The binding 
of control  antibodies,  McD  and  antibodies  from  L.  serum  were  not  significantly 
inhibited by the anti-idiotype F(ab')z. 
Studies of  lgG and DNA-Nucleoprotein Antigens Reactive with Bla tuRF.  Previous studies 
(8) have shown that Bla mRF reacts with aggregates of all subclasses of human IgG 
and  rabbit IgG but  not  moose, bovine, or sheep IgG. The  Fc,  but  not  the  F(ab')z, 1518  RHEUMATOID  FACTORS  THAT  CROSS-REACT  WITH  DNA-HISTONE 
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Fio.  4.  Inhibition of antigen binding of Bla mRF by dilutions of 1.5 mg/ml F(ab')~ preparation 
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tuRF  (0)  binding to IgG-Sepharose  (agg  IgG).  (B) Inhibition of 0.5 ,ttg 125I-sNP binding by Bla 
tuRF (©) and y-M anti-sNP from L. serum (Q). 
fragment when coupled to Sepharose will bind Bia mRF as effectively as the ligand 
made with the whole IgG molecule. From the inability of monomeric IgG and the Fc 
fragment  to  precipitate  with  Bla  mRF  and  analysis  of  the  binding  studies  with 
monomeric IgG, only one antigen site appears to be present on each IgG molecule. 
The nature of the DNA-protein reactive with Bla mRF was further characterized 
by gel  diffusion  and  immunofluorescent  studies.  There was no precipitation  in  gel 
diffusion between Bla tuRF and DNA, histone, or a preparation of the soluble nuclear 
antigens.  Mixtures  of DNA and  histones also failed to give precipitation;  however, 
preparations of nucleosomes precipitated with Bla mRF in gel diffusion. Polynucleo- 
some preparations >19S precipitated as well as the DNA-nucleoprotein preparation, 
whereas oligonucleosomes and the  t 1S mononucleosomes gave weaker lines. The role AGNELLO,  ARBETrER,  IBANEZ  DE  KASEP,  POWELL,  TAN,  AND JOSLIN  1519 
of histones in the DNA-protein antigen could be confirmed by the ANF technique of 
Tan et al. (15). In this method, elution of tissue nuclei with 0.1  N  HC1 eliminates the 
reaction of the anti-DNA histone antibodies with the tissue nuclei. The reactivity can 
be reconstituted by treatment  of the  tissue  with  isolated  histone  (16).  0.1  N  HCI 
treatment of tissue completely eliminates the ANF reaction of Bla mRF shown in Fig. 
1 A. The results of reconstitution experiments are summarized in Table I. From these 
studies it appears that the histone fraction H2A +  H2B is sufficient to reconstitute the 
nuclear antigen reactive with Bla tuRF. Although the histone fraction H3 +  H4 did 
not reconstitute, the possibility is not excluded that these histones in the nucleosome 
core are also reactive with Bla, because the presence of H3 and H4 in the reconstituted 
tissue was not confirmed in these experiments. 
Comparison of Interaction of Bla tuRF with Monomeric IgG and Mononucleosomes.  From 
binding  experiments  of Bla  with  monomeric  IgG,  the  valence  of Bla  mRF  for 
monomeric IgG determined was  5  and  the  association constant  (Ko):  3.75  ×  10  -6 
M -x. The comparable study of Bla binding with mononucleosomes could not be done 
because neither an active mononucleosome fragment with a single antigenic site nor 
an active Fab fragment of Bla could be prepared. However, because polynucleosomes 
could be radiolabeled without loss of reactivity with Bla mRF, inhibition by mono- 
meric IgG and mononucleosomes could be compared in binding assays using either 
IgG or the DNA-nucleoprotein antigen as the substrate. The results are shown in Fig. 
5. Where the binding of labeled nucleosomes by Bla was inhibited, the mononucleo- 
TABLE  1 
Characterization of Bla tuRF Antinuclear Reaction by O. 1 N HCl Tissue 
Extraction and Reconstitution with  Various Histone Fractions 
ANA Titer 
Control tissue  >- 1,000 
Extracted tissue  0 
Extracted tissue plus histone: 
Total  _ 1,000 
H1  0 
H2a +  H2b  _>1,000 
H3 +  H4  0 
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somes per mole gave greater inhibition than monomeric IgG. Where the binding of 
labeled monomeric IgG was inhibited, the mononucleosomes gave no inhibition. 
Occurrence of Polyclonal RF  Cross-Reactive with  DNA-Nucleoprotein.  Cross-reactivity 
similar  to  Bla  mRF  was  demonstrated  among  polyclonal  RF  from  a  variety  of 
pathologic  sera.  Because  precipitin  analysis  in  gel  diffusion  can  be  a  relatively 
insensitive  technique,  two additional  methods were  used  to assess  the  incidence of 
cross-reacting RF in  sera  in  various diseases,  blocking of ANF activity, or  12SI-sNP 
binding by aggregated IgG. The incidence of cross-reactive RF which was found in 
various diseases using the three methods is shown in Table II. Approximately 40% of 
sera from seropositive classic rheumatoid arthritis  (RA) contain cross-reactive RF. A 
high incidence is also found among the patients with the so-called rheumatoid overlap 
(RO) syndromes, but thus far, sera from RF-positive SLE patients have been negative. 
None of the RF from patients with mixed cryoglobulinemia tested were cross-reactive. 
Only a small group of mixed connective-tissue disease (MCTD) patients with positive 
RF tests were available for study; of these, in five of seven, the RF was cross-reactive. 
In  two  of  these  sera,  the  cross-reactive  RF  was  detectable  only  in  an  isolated 
preparation of RF from the serum although the routine tests for RF were positive. 
The RF of one of the positive MCTD sera available in large volume was isolated 
by IgG-Sepharose affinity chromatography in the same way Bla mRF was isolated. 
The precipitin reaction of the isolated Orl RF with DNA-nucleoprotein is shown in 
Fig. 6. DNase or trypsin digestion of the DNA nucleoprotein, as was the case for the 
Bla mRF reaction, eliminated the reaction with Orl. In contrast to Bla mRF, however, 
in the radioimmunoassay  , the Orl  polyclonal RF binding to aggregated IgG is not 
m~ximally inhibited by both aggregated IgG and DNA-nucleoprotein. Only -25% of 
the Orl RF binding is inhibited by DNA-nucleoprotein. 
Evidence  that  Orl  and  Bla  reacted  with  similar  antigenic  determinants  on  the 
DNA-nucleoprotein is shown in Table III. Both Bla and Orl react with DNA-histone 
H2A-H2B complex. 
Characterization of BLA  Cross-Idiotype.  Characterization of the previously described 
WA cross-idiotype using the method of antigen binding inhibition is shown in Fig. 7. 
Anti-McD  (anti-Ma  in  previous  studies),  which  has  specificity  for  the  WA cross- 
idiotype antigen, inhibits the binding of Wa mRF, but no inhibition is obtained with 
anti-Lay, which has specificity for the PO cross-idiotype antigen or with anti-Bla. Bla 
TABLE  II 
Incidence of Cross-Reactive RF 
Number of 
RF-positive  Gel diffu- 
patients  sion 
Number of patients positive: 
ANA*  NP bind-  Overall pos- 
ing:I:  itives 
Classic RA  62 
MCTD  7 
Overlap syndromes  10 
SLE  8 
Mixed cryoglobulinemia  11 
Miscellaneous  12 
16  22  18  27 
5  5  5  5 
6  4  4  4 
6  0  0  0 
0  0  0  0 
0  0  1  l 
* Blocked with aggregated IgG. 
:~ NP, nucleoprotein. Blocked with aggregated IgG. AGNELLO,  ARBE'I*rER,  IBANEZ  Da  KASEP,  POWELL,  TAN,  AND JOSLIN  1521 
Fro.  6.  0.6% agarose gel diffusion plate.  Precipitation of 1 mg/ml Bla tuRF and  1 mg/ml Orl 
polyclonal RF with sNP. 
TABLE  Ill 
Characterization of Orl Polyclonal RF Antinuclear Reaction by O. 1 N HCI 
Tissue Extraction and Reconstitution with Various Histone Fractions 
ANA titer 
Control tissue  256 
Extracted tissue  0 
Extracted tissue plus histone: 
Total  64 
HI  0 
H2a +  H2b  64 
H3 +  H4  0 
IOC 
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FIO.  7.  Inhibition of 0.2 #g l~I-Wa binding to IgG-Sepharose by dilutions of absorbed F(ab')= 
preparations of anti McD (A), anti-Bla (O), and anti-Lay (ll). Starting concentration of antisera 
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mRF was not inhibited by either anti-McD or anti-Lay and, hence, did not appear to 
belong to either the WA or PO groups. The anti-Lay used in these experiments was 
previously shown  to  inhibit  Pom  in  the  hemagglutination  system  (3).  In  the  assay 
used here, this antiserum showed no inhibition of Pom binding to antigen,  but gave 
strong inhibition  of Lay binding to antigen.  The same results were obtained with a 
second antisera raised to Lay. 
The identification and isolation of another RF, Orl, with cross-reactivity similar to 
Bla mRF allowed studies to determine if a BLA cross-idiotype existed.  Fig. 8 A shows 
the inhibition by anti-Bla of the polyclonal Orl and four tuRF that do not cross react 
with DNA-nucleoprotein, two of the WA group  (Wa and McD)  and two of the PO 
group  (Pom  and  Lay).  To be  certain  that  the  Orl  inhibition  was  significant,  each 
point  was  done  in  quadruplicate.  Two  standard  deviations  for  each  point  were 
determined and compared to inhibition of Orl by anti-McD. The inhibition of Orl by 
anti-Bla was clearly significant  by this analysis.  Similar results were obtained with a 
second  antisera  to  Bla  raised  in  a  rabbit  and  one raised  in  a  goat.  The  results  are 
consistent with the percentage ofOrl RF binding to aggregated IgG that was inhibited 
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Flc.  9.  Characterization ofanti-Orl cross-idiotypic specificity by antigen-binding inhibition stud- 
ies.  (A)  Inhibition  of 0.2 #g l~fI-Bla  mRF  binding  to IgG-Sepharose  by anti-Orl  (O),  anti-McD 
(&), and anti-Lay (m). (B) Inhibition of 0.5 #g 125I-polynucleosome  binding by Bla and rnRF with 
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by DNA-nucleoprotein and indicate that only a  portion of the Orl RF preparation 
bears the BLA eross-idiotype. That this is most likely the ease is supported by studies 
of inhibition of Orl RF binding to nueleosomes (Fig. 8 B). Whereas anti-Bla could 
inhibit only 18% of Orl aggregated-IgG binding, the same antisera could inhibit 78% 
of the Orl nucleosome binding. The existence of a BLA cross-idiotype was confirmed 
by an anti-Orl serum that inhibited Bla binding to aggregated IgG but did not inhibit 
the aggregate binding of the proteins of the WA and PO groups. Fig. 9 A and B shows 
the studies  defining the  BLA cross-idiotype using this  anti  sera.  Anti  OH  inhibits 
Bla  binding  to  both  aggregated  IgG  and  nucleosomes, whereas  anti-McD,  which 
defines the WA group, and anti-Lay which defines the PO group, give insignificant 
inhibition. 
Discussion 
This study provides clear evidence for the cross-reactivity of an mRF,  Bla, with 
DNA-nucleoprotein. In addition, evidence is present that  the combining site of Bla 
mRF  is  involved  in  the  cross-reactivity. This  is  the  first  monoclonal  IgM  anti-y- 
globulin studied to have this unique reactivity. Similar to the polyclonal RF~cross- 
reactive with nuclei studied by Hannestad and Stollar (17), Bla mRF appears to react 
with an antigen on the nucleosome core which is known to consist of DNA and two 
molecules each of H2A, H2B, H3, and H4 (18). Our studies on the antigen reactive 
with  Bla  mRF  indicate:  (a)  both  DNA  and  histone  are  involved  in  the  antigen 
determinant; (b) H2A +  H2B when added to nuclei stripped of histone is sufficient to 
reconstitute the antigen; (c) the determinant is destroyed by trypsin treatment which 
is  known  to cleave 20-30  amino  acid  residues  from the  NH2-terminus  of all  four 
histones while leaving the remainder of the molecules and gross nucleosome structure 
intact (18). Because there are no known primary structural similarities between DNA 
histone and IgG which would explain the cross-reactivity, there must be some other 
type of molecular similarity. The finding that  the antigenic determinant  could be 
reconstituted by adding histone to nuclei extracted with 0.1 N HCI suggests that some 
retained organization of the DNA in the extracted nuclei is sufficient to orient the 
histones to produce the antigenic determinant. 
The cross-reactivity of Bla mRF raises the question of the relationship of IgG and 
DNA-histone to the immunogen. Exhaustive attempts at answering this question by 
determining the K0 of Bla mRF for the IgG and DNA-histone antigen were unsuc- 
cessful because the  Ko for DNA-histone  needed could not  be determined with  the 
methodology employed. The 3.75 ×  10  -s M -x Ko obtained for monomeric IgG is low, 
like that  of other RF  and, therefore, uninformative.  However, from the inhibition 
studies done, it could be concluded that the affinity of Bla mRF must be greater for 
IgG than for DNA-histone. These data suggest that neither IgG nor DNA-histone fit 
the combining site of Bla mRF sufficiently well to give high Ko and that of the two, 
DNA-histone gives the weaker reaction. It is possible that neither of these antigens is 
the immunogen and that their reactions with Bla mRF are the result of the presence 
of structures which coincidentally partially  fit the combining site of this antibody. 
However, the occurrence of a  somewhat analogous cross-reactivity, Clq'interaction 
with both IgG and DNA, suggests that the phenomenon may not be  just happenstance. 
Some of these studies  are similar to the studies on antibodies cross-reactive with 
menadione  and  2,4-dinitrophenyl  (19,  20)  in  that  evidence  is  presented  for  the 1524  RHEUMATOID FACTORS THAT CROSS-REACT WITH  DNA-HISTONE 
specificity of the reaction of antibodies cross-reactive with two structurally unrelated 
antigens,  IgG and DNA-histone. Additional  evidence for the specificity of the com- 
bining site of Bla mRF for DNA-histone is that complement is activated by complexes 
of Bla  and  DNA-histone  (R.  Powell  and  V.  Agnello.  Unpublished  observations.). 
Another  manifestation  of this  biologic  activity  is  that  Bla  can  induce  the  lupus 
erythematosus  (LE)  cell  reaction  (7),  which  is  known  to  require  the  fixation  of 
complement after the  reaction  of antibody,  with  the  DNA-nucleoprotein  from dis- 
rupted nuclei. 
Studies  on  Bla  mRF,  although  of interest  in  their  own  right,  take  on  greater 
significance with the finding reported  in  this study that  similar cross-reactive poly- 
clonal  RF  occur  in  a  variety of human  diseases.  These  findings  confirm  previous 
reports of RF  in  RA that  cross-react with  nuclear  antigens  (5,  21-23).  The higher 
incidence  found  in our study may in  fact be still  higher.  Our  finding  that  some of 
these  cross-reactive RF  can  be  detected  only after  isolation  on  IgG-Sepharose has 
recently  been  confirmed  by Johnson  (23)  who  found  the  isolated  RF  in  14  of  15 
random seropositive RA sera gave positive ANF reactions, and by Tipton et al.  (24) 
who found 10 of 15 isolated RF had ANF activity. The broader screening done in our 
study indicates that the cross-reactive type of RF is not confined to RA but occurs in 
other diseases as well. 
However, this type of RF does not invariably occur in all RF-positive sera as shown 
by the studies of idiopathic mixed cryoglobulinemia where no cross-reactive RF were 
found even after isolation studies on each serum. The cross-reactive RF also was not 
found in SLE and a number of miscellaneous seropositive diseases; however, isolation 
studies were not done in these groups; hence, their occurrence is not totally excluded. 
The wide occurrence of polyclonal RF with cross-reactivity similar to the Bla mRF 
raised the possibility that these RF constituted a distinct subset. The finding that one 
representative isolated polyclonal RF, Orl, in comparative studies appeared to react 
with  the  same  nuclear  antigen  as  Bla  mRF  was  consistent  with  this  hypothesis. 
Additional evidence that these antibodies were related was obtained by cross-idiotype 
studies.  It  had  previously been established  that  two cross-idiotype groups,  PO  and 
WA, existed among monoclonal anti-y-globulin and recently it has been reported that 
these and other cross-idiotypes were present among polyclonal RF  (25,  26).  Because 
a  second  monoclonal  RF  with  DNA-histone  cross-reactivity was  not  available,  the 
demonstration  of the BLA cross-idiotype was somewhat difficult  because the study 
required use of a polyclonal RF, only a relatively small portion of which cross-reacted 
with  DNA-nucleoprotein.  The method which  was  found  to best  demonstrate cross- 
idiotype  was  direct  inhibition  of  antigen  binding  by  F(ab')2  preparation  of  the 
absorbed  typing antisera.  By using  this  technique,  it  was  possible  to  compare  the 
inhibition of Bla and Orl binding to both IgG and DNA-nucleoprotein.  Using three 
antisera  raised  to  Bla,  one  to  Orl  and  established  WA  and  PO  typing sera,  clear 
evidence was obtained  for a  cross-idiotype antigen  on  Bla  and  Orl  RF  which  was 
completely distinct  from the WA and PO cross-idiotypes. 
It should be noted that there appears to be some difference in the antigen-binding 
inhibition  and  the hemagglutination  methods  in  defining cross-idiotype groups be- 
cause the  WA  group  could  be defined  by both  techniques,  whereas  the  PO  group 
could be defined only by the hemagglutination method. It is possible that the antigen- 
binding inhibition  technique defines only those idiotypes relating to combining site, AGNELLO, ARBETTER, IBANEZ DE KASEP, POWELL, TAN, AND JOSLIN  1525 
whereas the hemagglutination  inhibition detects a  broader range of cross-idiotypes 
which do not necessarily involve the combining site. 
Previous studies on anti-y-globulins could not relate cross-idiotypes to the specificity 
of each anti-'y-globulin for different subclasses of human IgG or rabbit  IgG. In our 
study, there is a clear correlation between BLA idiotype and reactivity with the DNA- 
histone antigen. Thus far, none of the proteins in the WA and PO groups tested react 
with DNA-histone and none bore the BLA cross-idiotype. Capra and Kehoe (27) have 
postulated a relationship between cross-idiotypes, combining sites, and hypervariable 
regions based  on  the  similarity of the  amino  acid  sequences of the  hypervariable 
regions of two of the proteins in the PO group, Lay and Pore. The lack of a  known 
unique antigen specificity for the PO group limits, in part, the interpretation of those 
data. Amino acid-sequence studies currently being done on the Bla and Wa proteins 
when compared to the sequences already available on Pom and  Lay may provide 
more specific information on relationship between cross-idiotype and antibody-com- 
bining site structure.  2 
The relationship if any of RF of different specificities to pathologic mechanisms or 
etiology in those diseases where they occur is unknown. From the studies presented 
here, one possible relationship is apparent. DNA-nucleoprotein has been demonstrated 
in various pathologic fluids from patients with RA  (28). The presence of RF cross- 
reactive with DNA-nucleoprotein in such fluids could, therefore, have immunopath- 
ologic consequences through immune-complex formation. 
Summary 
Cross-reactivity of a monoclonal rheumatoid factor with an antigen present on IgG 
and DNA-nucleoprotein was demonstrated, and evidence presented that the combin- 
ing  site of the  antibody was  involved in  the  reaction.  The antigen  on  the  DNA- 
nucleoprotein was shown to involve both DNA and histone fraction H2A +  H2B and 
was  trypsin sensitive. The relative binding affinity of the antibody appeared to be 
greater for IgG than the DNA-histone antigen. 
Similar  polyclonal cross-reactive rheumatoid  factors were  found in  a  variety of 
diseases. A high incidence was found among patients with rheumatoid arthritis and 
mixed connective tissue disease. None were detected in patients with systemic lupus 
erythematosus and idiopathic cryoglobulinemia. Studies on one representative isolated 
polyclonal rheumatoid  factor demonstrated  the same  reactivity with  DNA-histone 
H2A +  H2B as the monoclonal antibody. Cross-idiotype studies using antigen-binding 
inhibition methods demonstrated the same cross-idiotype on the polyclonal and the 
monoclonal rheumatoid factor which reacted with DNA-histone. This cross-idiotype 
was shown to be distinct from the cross-idiotypes previously demonstrated on mono- 
clonal IgM proteins with anti-'y-globulin activity. 
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